全文获取类型
收费全文 | 1915篇 |
免费 | 116篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 24篇 |
儿科学 | 40篇 |
妇产科学 | 39篇 |
基础医学 | 281篇 |
口腔科学 | 28篇 |
临床医学 | 155篇 |
内科学 | 371篇 |
皮肤病学 | 60篇 |
神经病学 | 149篇 |
特种医学 | 69篇 |
外科学 | 242篇 |
综合类 | 9篇 |
预防医学 | 149篇 |
眼科学 | 60篇 |
药学 | 176篇 |
中国医学 | 3篇 |
肿瘤学 | 179篇 |
出版年
2023年 | 15篇 |
2022年 | 32篇 |
2021年 | 57篇 |
2020年 | 38篇 |
2019年 | 37篇 |
2018年 | 42篇 |
2017年 | 40篇 |
2016年 | 48篇 |
2015年 | 53篇 |
2014年 | 59篇 |
2013年 | 87篇 |
2012年 | 154篇 |
2011年 | 166篇 |
2010年 | 81篇 |
2009年 | 79篇 |
2008年 | 152篇 |
2007年 | 141篇 |
2006年 | 111篇 |
2005年 | 121篇 |
2004年 | 121篇 |
2003年 | 107篇 |
2002年 | 106篇 |
2001年 | 24篇 |
2000年 | 18篇 |
1999年 | 24篇 |
1998年 | 17篇 |
1997年 | 5篇 |
1996年 | 15篇 |
1995年 | 4篇 |
1994年 | 6篇 |
1993年 | 5篇 |
1992年 | 9篇 |
1991年 | 8篇 |
1990年 | 7篇 |
1989年 | 7篇 |
1988年 | 3篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1984年 | 4篇 |
1982年 | 5篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1979年 | 2篇 |
1977年 | 2篇 |
1971年 | 2篇 |
1965年 | 1篇 |
1964年 | 1篇 |
1963年 | 1篇 |
1962年 | 1篇 |
1961年 | 1篇 |
排序方式: 共有2034条查询结果,搜索用时 15 毫秒
81.
Yohei Yamamoto Aki Nishijima‐Matsunobu Yuko Hiroshima Katsuhiko Enomoto Masahiro Inoue Osamu Muto Maya Suzuki Hiroshi Nanjo Hiroyuki Shibata Yasufumi Omori 《Pathology international》2020,70(3):171-178
Desmoplastic small round cell tumor (DSRCT) is a rare aggressive malignant tumor. It is a refractory tumor and the median overall survival is very short. We report two autopsy cases of DSRCT, both of which were already advanced and metastasized at the first medical examination. Both cases showed typical DSRCT findings in terms of localization of the lesions, histopathology and genetics, but the rate of disease progression was quite different. Survival after initial symptoms in Case 1 was only 12 months. On the other hand, survival after primary hospitalization in Case 2 was 42 months. The Case 2 patient initially received chemotherapy for advanced pancreatic carcinoma, because a nodule of the pancreatic tail was found on computed tomography (CT) scan. After chemotherapy, tumor regression was observed on CT scan. It is thus implied that adoption of the regimen for pancreatic carcinoma might have been one of reasons of the long survival in Case 2. 相似文献
82.
Aki Semih Özden Ali Veysel Alptekin Hasan Kerem Öncü Alptekin Jülide 《Manuelle Medizin》2020,58(4-5):237-245
Manuelle Medizin - The current study was designed to compare the short-term effects of chiropractic applications (diversified technique) and dry needling on chronic mechanical neck pain.... 相似文献
83.
Kazuyoshi Uchihashi Toshiyuki Tsuruta Hiroko Mine Shigehisa Aoki Aki Nishijima‐Matsunobu Mihoko Yamamoto Akio Kuraoka Shuji Toda 《Pathology international》2014,64(6):276-282
Stenosing flexor tenosynovitis, trigger finger, is a common clinical disorder causing painful locking or contracture of the involved digits, and most instances are idiopathic. This problem is generally caused by a size mismatch between the swollen flexor tendon and the thickened first annular pulley. Although hypertrophic pulleys have been histologically and ultrasonographically detected, little is known about the histopathology of the tenosynovium covering the tendons of trigger fingers. We identified chondrocytoid cells that produced hyaluronic acid in 23 (61%) fingers and hypocellular collagen matrix in 32 (84%) fingers around the tenosynovium among 38 specimens of tenosynovium from patients with trigger fingers. These chondrocytoid cells expressed the synovial B cell marker CD44, but not the chondrocyte marker S‐100 protein. The incidence of these findings was much higher than that of conventional findings of synovitis, such as inflammatory infiltrate (37%), increased vascularity (37%), hyperplasia of synovial lining cells (21%), or fibrin exudation (5%). We discovered the following distinctive histopathological features of trigger finger: hyaluronic acid‐producing chondrocytoid cells originated from fibroblastic synovial B cells, and a hypocellular collagen matrix surrounding the tenosynovium. Thus, an edematous extracellular matrix with active hyaluronic acid synthesis might increase pressure under the pulley and contribute to the progression of stenosis. 相似文献
84.
85.
Tatsuki Ueda Ayako Kumagai Shoichi Iriguchi Yutaka Yasui Tadayo Miyasaka Kengo Nakagoshi Kazuki Nakane Keigo Saito Mari Takahashi Aki Sasaki Shinsuke Yoshida Naoko Takasu Hiroshi Seno Yasushi Uemura Koji Tamada Tetsuya Nakatsura Shin Kaneko 《Cancer science》2020,111(5):1478-1490
The use of allogeneic, pluripotent stem‐cell‐derived immune cells for cancer immunotherapy has been the subject of recent clinical trials. In Japan, investigator‐initiated clinical trials will soon begin for ovarian cancer treatment using human leukocyte antigen (HLA)‐homozygous‐induced pluripotent stem cell (iPSC)‐derived anti–glypican‐3 (GPC3) chimeric antigen receptor (CAR)‐expressing natural killer/innate lymphoid cells (NK/ILC). Using pluripotent stem cells as the source for allogeneic immune cells facilitates stringent quality control of the final product, in terms of efficacy, safety and producibility. In this paper, we describe our methods for the stable, feeder‐free production of CAR‐expressing NK/ILC cells from CAR‐transduced iPSC with clinically relevant scale and materials. The average number of cells that could be differentiated from 1.8‐3.6 × 106 iPSC within 7 weeks was 1.8‐4.0 × 109. These cells showed stable CD45/CD7/CAR expression, effector functions of cytotoxicity and interferon gamma (IFN‐γ) production against GPC3‐expressing tumor cells. When the CAR‐NK/ILC cells were injected into a GPC3‐positive, ovarian‐tumor‐bearing, immunodeficient mouse model, we observed a significant therapeutic effect that prolonged the survival of the animals. When the cells were injected into immunodeficient mice during non–clinical safety tests, no acute systemic toxicity or tumorigenicity of the final product or residual iPSC was observed. In addition, our test results for the CAR‐NK/ILC cells generated with clinical manufacturing standards are encouraging, and these methods should accelerate the development of allogeneic pluripotent stem cell‐based immune cell cancer therapies. 相似文献
86.
Matti O. Ruuskanen Pande P. Erawijantari Aki S. Havulinna Yang Liu Guillaume Mric Jaakko Tuomilehto Michael Inouye Pekka Jousilahti Veikko Salomaa Mohit Jain Rob Knight Leo Lahti Teemu J. Niiranen 《Diabetes care》2022,45(4):811
OBJECTIVETo examine the previously unknown long-term association between gut microbiome composition and incident type 2 diabetes in a representative population cohort.RESEARCH DESIGN AND METHODSWe collected fecal samples from 5,572 Finns (mean age 48.7 years; 54.1% women) in 2002 who were followed up for incident type 2 diabetes until 31 December 2017. The samples were sequenced using shotgun metagenomics. We examined associations between gut microbiome composition and incident diabetes using multivariable-adjusted Cox regression models. We first used the eastern Finland subpopulation to obtain initial findings and validated these in the western Finland subpopulation.RESULTSAltogether, 432 cases of incident diabetes occurred over the median follow-up of 15.8 years. We detected four species and two clusters consistently associated with incident diabetes in the validation models. These four species were Clostridium citroniae (hazard ratio [HR] 1.21; 95% CI 1.04–1.42), C. bolteae (HR 1.20; 95% CI 1.04–1.39), Tyzzerella nexilis (HR 1.17; 95% CI 1.01–1.36), and Ruminococcus gnavus (HR 1.17; 95% CI 1.01–1.36). The positively associated clusters, cluster 1 (HR 1.18; 95% CI 1.02–1.38) and cluster 5 (HR 1.18; 95% CI 1.02–1.36), mostly consisted of these same species.CONCLUSIONSWe observed robust species-level taxonomic features predictive of incident type 2 diabetes over long-term follow-up. These findings build on and extend previous mainly cross-sectional evidence and further support links between dietary habits, metabolic diseases, and type 2 diabetes that are modulated by the gut microbiome. The gut microbiome can potentially be used to improve disease prediction and uncover novel therapeutic targets for diabetes. 相似文献
87.
88.
Takaaki Konuma Satoshi Takahashi Jun Ooi Akira Tomonari Nobuhiro Tsukada Seiko Kato Aki Sato Fumihiko Monma Senji Kasahara Tokiko Nagamura-Inoue Kaoru Uchimaru Tohru Iseki Arinobu Tojo Takuhiro Yamaguchi Shigetaka Asano 《Annals of hematology》2009,88(6):581-588
Increasing recipient age is a well-known risk factor for graft-versus-host disease (GVHD) and treatment-related mortality
(TRM) and has a negative impact on allogeneic hematopoietic stem cell transplantation. Since the incidence of severe GVHD
after cord blood transplantation (CBT) is lower than that after transplants using bone marrow or mobilized peripheral blood
grafts from adult cells, we should expect better outcomes from CBT in older patients. To evaluate the feasibility and efficacy
of myeloablative unrelated CBT in patients aged between 50 and 55 years, we performed a retrospective comparison of 100 patients
with acute leukemia who received cord blood grafts at our institution. Nineteen older patients (median age, 52; range, 50–55)
and 81 younger patients (median, 36; range, 16–49) received a myeloablative conditioning regimen including 12 Gy of total
body irradiation and chemotherapy. GVHD prophylaxis included cyclosporine with (n = 96) or without (n = 4) methotrexate. There were no significant differences in the incidences of grades II to IV acute GVHD, extensive-type
chronic GVHD, TRM, and the probability of overall and disease-free survival between these groups. These results suggest that,
in patients with acute leukemia, myeloablative CBT might be as safe and effective in patients aged between 50 and 55 years
as in younger patients. 相似文献
89.
Hiroyuki Fujita Minoru Yoshida Katsuhiro Miura Tetsuaki Sano Katsuyuki Kito Masatomo Takahashi Kazuyuki Shigeno Yoshinobu Kanda Nobu Akiyama Naoko Hatsumi Kazunori Ohnishi Shuichi Miyawaki Tomoki Naoe 《International journal of hematology》2009,90(2):191-198
Guidelines for the management of febrile neutropenia (FN), deep fungal infection or use of granulocyte colony-stimulating
factor (G-CSF) published in the US and Europe cannot be directly applied in other countries. In this study, we undertook a
questionnaire survey of member institutions of the Japan Adult Leukemia Study Group to investigate the status of, and problems
with, the management of infectious complications in patients with acute leukemia. The questionnaire consisted of 52 multiple-choice
questions covering therapeutic environment, antibacterial, and antifungal prophylaxis, empirical therapy (ET) for FN, and
use of G-CSF. The results were compared to a previous survey performed in 2001. Usable responses were received from 134 of
184 (71.7%) institutions. With regard to antibacterial prophylaxis, fluoroquinolones and sulfamethoxazole-trimethoprim were
most commonly used. Regarding antifungal prophylaxis, the most frequently used agent was fluconazole, followed by itraconazole.
In ET for FN, monotherapy with cephems or carbapenems accounted for almost all of the responses. Most respondents indicated
that they used micafungin (MCFG) in ET. Prophylactic use of G-CSF during remission induction therapy in acute myeloid leukemia
was reported by only 4% of respondents. Strategies for antibacterial and antifungal prophylaxis or treatment of FN should
be reviewed and updated as needed. 相似文献
90.